Eli Lilly: to present data on imlunestrant

(CercleFinance.com) - Eli Lilly has announced that data from the Phase 3 trial of imlunestrant, an oral selective estrogen receptor degrader (SERD), will be presented for the first time at the San Antonio Breast Cancer Symposium (SABCS) to be held December 10-13 in San Antonio, Texas.


The trial evaluates imlunestrant alone or in combination with Verzenio in patients with ER+ and HER2- advanced breast cancer, pre-treated with endocrine therapy.

Lilly will also present an analysis of recurrence risk according to nodal status and high-risk features for early HR+ and HER2- breast cancers, as well as preclinical and phase 1 data for the selective PI3Ka-mutated inhibitors LY4045004 and LOXO-783.


Copyright (c) 2024 CercleFinance.com. All rights reserved.